NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics has been notified that it has failed to meet the Nasdaq's minimum bid price requirement for continued listing on the exchange, the company disclosed yesterday in a filing with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.